Related Experiment Videos
Angiogenesis in rheumatoid arthritis
1Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, UK. e.paleolog@ic.ac.uk
Arthritis Research
|July 12, 2002
Summary
Targeting angiogenesis, the formation of new blood vessels, is a promising strategy for rheumatoid arthritis (RA). Inhibiting vascular endothelial growth factor (VEGF) in animal models reduced RA disease severity and joint destruction.
Area of Science:
- Rheumatology
- Immunology
- Vascular Biology
Background:
- Rheumatoid arthritis (RA) involves synovial lining expansion and pannus invasion of cartilage and bone.
- This process requires increased vascular supply to the synovium for oxygen and nutrient delivery.
- Angiogenesis, the formation of new blood vessels, is critical for pannus development and maintenance in RA.
Purpose of the Study:
- To investigate the role of angiogenesis and vascular endothelial growth factor (VEGF) in rheumatoid arthritis pathogenesis.
- To evaluate the therapeutic potential of targeting angiogenesis in RA models.
Main Methods:
- Review of existing literature on angiogenesis in RA.
- Analysis of the role of VEGF as a proangiogenic and vascular permeability factor in RA.
- Inhibition of VEGF activity using a soluble VEGF receptor in a murine collagen-induced arthritis model.
Main Results:
- VEGF plays a central role in the angiogenic process in RA and contributes to joint swelling.
- Targeting angiogenesis in animal models of arthritis has shown disease amelioration.
- Inhibition of VEGF activity in a murine model reduced disease severity, paw swelling, and joint destruction.
Conclusions:
- Blockade of angiogenesis, particularly VEGF, is a promising therapeutic strategy for rheumatoid arthritis.
- Further clinical investigation into anti-angiogenic therapies for RA is warranted.